PROTAC LCK Tyrosine Kinase Degradation via Cereblon Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a scarcity of compounds that are potent, efficacious, and selective modulators of protein degradation, particularly for targeting cereblon and LCK tyrosine kinase, which are involved in cancer and other cellular proliferation disorders.
Innovation Solution
The development of proteolysis-targeting chimeric molecules (PROTACs) that specifically induce the degradation of LCK tyrosine kinase, utilizing substituted N-(2-chloro-6-methylphenyl)-2-((6-(6-membered heterocycloalkyl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide analogues to target both cereblon and LCK tyrosine kinase for therapeutic modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional protein degradation modulators are used, then some protein degradation activity is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The PROTAC molecule is segmented into three functional modules: (1) a LCK binder moiety that specifically binds to LCK tyrosine kinase, (2) a cereblon binder moiety that recruits the E3 ubiquitin ligase complex, and (3) a linker that connects the two binders. This segmentation allows each module to independently perform its function, achieving high potency and selectivity while enabling systematic optimization of each component
Solution Approach 2:
The cereblon protein serves as an intermediary in the degradation process. The PROTAC molecule binds to LCK and simultaneously recruits cereblon, which then acts as an E3 ubiquitin ligase to ubiquitinate LCK, marking it for proteasomal degradation. This intermediary mechanism enables targeted degradation without requiring direct inhibition of LCK's catalytic activity
2Reliability
If PROTAC molecules are designed to target both cereblon and LCK, then selective protein degradation is achieved, but molecular complexity increases
Solution Approach 1:
The PROTAC molecule is constructed as a composite structure combining two distinct binder moieties with different binding specificities (LCK binder and cereblon binder) connected by a linker. This composite architecture integrates multiple functional properties into a single molecule, enabling simultaneous recognition of both LCK and cereblon while maintaining solubility and stability through careful selection of linker chemistry
Solution Approach 2:
The cereblon binder moiety provides universal functionality by recruiting the cereblon-E3 ubiquitin ligase complex, which can ubiquitinate various substrates. This multi-functional design allows the same PROTAC scaffold to potentially target different proteins by changing only the LCK binder portion while retaining the cereblon recruitment capability
3Reliability
If high potency modulation is achieved through targeted degradation, then therapeutic efficacy improves, but development of such compounds is scarce
Solution Approach 1:
The patent performs preliminary optimization of the PROTAC scaffold by systematically varying the linker length, composition, and chemistry, as well as optimizing the binding affinity of both LCK and cereblon binder moieties before preclinical evaluation. This preliminary action ensures that the most potent and selective analogues are selected for further development, reducing the scarcity of efficacious compounds
Solution Approach 2:
The patent employs parameter changes by modifying key molecular parameters including linker length (number of atoms), linker flexibility (rigid vs. flexible linkers), electrostatic properties (charged vs. uncharged groups), and hydrophobicity to optimize the balance between potency, selectivity, solubility, and pharmacokinetic properties, thereby improving therapeutic efficacy and manufacturability
Data Source
AI summary
In one aspect, the disclosure relates to proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of LCK tyrosine kinase, i.e., the disclosed substituted N-(2-chloro-6-methylphenyl)-2-((6-(6-membered heterocycloalkyl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide analogues. The disclosed compounds are useful for modulating LCK tyrosine kinase activity through targeted degradation. In further aspects, the present disclosure relates to methods of making the disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with a LCK tyrosine kinase dysfunction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.